Guardion Health Sciences, Inc. GHSI Income Statement

Guardion health sciences, inc. (GHSI)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16
Revenue
Medical foods
-	-	-	-	-	-	-	-	72	-	-	-	-	-	-	-	-
Vision testing diagnostics
-	-	-	-	-	-	-	-	120	-	-	-	-	-	-	-	-
Total Revenue
245	238	161	260	242	234	294	220	193	-	-	-	-	-	-	-	-
Total revenue
-	-	-	-	-	-	-	-	-	-	62	59	-	-	-	-	-
Cost of goods sold
Medical foods
-	-	-	-	-	-	-	-	32	-	-	-	-	-	-	-	-
Vision testing diagnostics
-	-	-	-	-	-	-	-	47	-	-	-	-	-	-	-	-
Revenue
-	-	-	-	-	-	-	-	-	-	-	-	55	48	33	29	29
Total Cost of goods sold
109	79	70	97	93	105	125	87	79	93	30	29	22	25	22	12	14
Gross profit
136	158	90	163	149	128	168	133	113	165	32	30	33	23	10	16	14
Operating expenses
Research and development
31	55	31	77	29	33	4	34	159	128	105	15	10	-9	20	12	10
Sales and marketing
488	663	448	409	353	296	240	378	605	305	116	101	76	95	85	104	103
General and administrative
1,952	1,966	2,022	2,489	947	1,154	1,064	1,034	1,680	1,925	1,392	766	598	1,056	765	893	623
Total operating expenses
2,472	4,249	2,502	2,976	1,330	1,483	1,309	1,447	2,446	2,358	1,614	884	685	1,391	872	1,009	737
Loss from operations
-2,336	-4,090	-2,412	-2,812	-1,181	-1,355	-1,140	-1,314	-2,332	-2,193	-1,581	-853	-652	-1,368	-861	-993	-722
Other expenses:
Interest expense
1	2	4	234	17	0	0	0	0	2	2	1	16	241	279	357	226
Finance cost upon issuance of warrants
-	-	-	229	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative warrants
8	-219	-31	-227	186	-	-	-	-	-	0	0	-	-	-	-	-
Costs associated with extension of warrant expiration dates
-	-	-	-	-	-	1,007	494	-	-	-	-	-	-	-	-	-
Total other expenses
10	-31	-27	236	203	120	1,007	495	0	-	-2	-1	-	-	-	-	-
Total other expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	357	226
Net loss
-2,346	-4,059	-2,385	-3,048	-1,385	-1,475	-2,148	-1,810	-2,333	-2,196	-1,584	-855	-669	-2,307	-1,141	-1,350	-949
Accretion of deemed dividend
-	-	-	-	-	-	-	-	-	266	249	53	31	547	185	27	0
Dividend declared
-	-	-	-	-	-	-	-	-	148	78	45	36	21	11	1	0
Net loss attributable to common shareholders
-	-	-	-	-	-	-	-	-	-2,611	-1,912	-954	-736	-2,877	-1,337	-1,379	-949
Net loss per common share - basic and diluted
-0.03	-0.02	-0.07	-0.14	-0.07	-0.06	-0.11	-0.09	-0.12	-0.31	-0.07	-0.04	-0.03	-0.13	-0.06	-0.06	-0.05
Weighted average common shares outstanding - basic and diluted
78,630	66,589	36,035	22,537	20,709	20,267	20,164	20,164	20,157	-20,319	25,825	25,470	24,760	23,496	21,424	21,315	20,966
Medical Foods [Member]
Total Revenue
139	127	112	104	99	-	86	79	-	-	-	-	-	-	-	-	-
Total Cost of goods sold
66	34	41	40	38	-	37	40	-	-	-	-	-	-	-	-	-
Gross profit
73	92	71	63	61	-	49	39	-	-	-	-	-	-	-	-	-
Total operating expenses
2,248	4,650	1,124	1,175	1,076	-	574	893	-	-	-	-	-	-	-	-	-
Loss from operations
-2,175	-4,557	-1,053	-1,111	-1,015	-	-525	-854	-	-	-	-	-	-	-	-	-
Medical Devices [Member]
Total Revenue
91	-	-	-	142	-	-	-	-	-	-	-	-	-	-	-	-
Total Cost of goods sold
40	-	-	-	55	-	-	-	-	-	-	-	-	-	-	-	-
Gross profit
50	-	-	-	87	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
116	-	-	-	205	-	-	-	-	-	-	-	-	-	-	-	-
Loss from operations
-65	-	-	-	-117	-	-	-	-	-	-	-	-	-	-	-	-
Vision Testing Diagnostics [Member]
Total revenue
-	-	44	150	-	-	208	140	-	-	-	-	-	-	-	-	-
Total cost of goods sold
-	-	27	53	-	-	88	46	-	-	-	-	-	-	-	-	-
Gross profit
-	-	16	96	-	-	119	93	-	-	-	-	-	-	-	-	-
Total operating expenses
-	-	142	206	-	-	110	85	-	-	-	-	-	-	-	-	-
Loss from operations
-	-	-126	-109	-	-	9	8	-	-	-	-	-	-	-	-	-
Other [Member]
Total Revenue
14	-	3	6	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Cost of goods sold
2	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-	-